Both in Pharmaceuticals
DiaMedica Therapeutics vs Bicara Therapeutics
Over the past year DMAC returned +60.5% and BCAX returned −39.7%; their daily moves had a correlation of 0.06.
DMAC +60.5% BCAX −39.7%Growth of $1, one year, split-adjusted
| Metric | DMAC | BCAX |
|---|---|---|
| Price | $10.77 | $8.89 |
| Market cap | $580.8M | $588.3M |
| Today | +7.70% | −0.78% |
| 1 month | +32.5% | −46.3% |
| 6 months | +65.2% | −62.6% |
| Year to date | +35.3% | −47.2% |
| 1 year | +58.4% | −44.4% |
| Revenue growth (YoY) | — | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | $43.5M | $497.3M |
| Dividend yield | — | — |
| Volatility (60d) | 56.2% | 131.9% |
| Short % of float | 21.5% | 23.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).